MedTrace Logo

Enoblituzumab Plus Retifanlimab or Tebotelimab in Head and Neck Cancer

NCT04634825 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 62

Last updated 2023-12-20

Study results available
· View outcomes & findings →

Summary

This is a Phase 2 study of enoblituzumab combined with either retifanlimab or tebotelimab administered as first-line treatment to patients with recurrent or metastatic squamous cell carcinoma of the head and neck.

Conditions

Interventions

BIOLOGICAL

Enoblituzumab

Anti-B7-H3 antibody

BIOLOGICAL

Retifanlimab

Anti-PD-1 antibody

BIOLOGICAL

Tebotelimab

PD-1 X LAG-3 bispecific DART molecule

Sponsors & Collaborators

Principal Investigators

  • Ashley L. Ward, MD · MacroGenics

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-17
Primary Completion
2022-07-29
Completion
2022-07-29
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Bulgaria
  • Hungary
  • Poland
  • Spain
  • Ukraine

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04634825 on ClinicalTrials.gov